Fusion Pharmaceuticalsinc Stock Beneish M Score
| FUSN Stock | USD 21.32 0.06 0.28% |
Fusion | Beneish M Score |
At this time, it appears that Fusion PharmaceuticalsInc is a possible manipulator. The earnings manipulation may begin if Fusion PharmaceuticalsI's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Fusion PharmaceuticalsI executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Fusion PharmaceuticalsI's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-2.2
Beneish M Score - Possible Manipulator
Fusion PharmaceuticalsI Beneish M-Score Indicator Trends
The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Fusion PharmaceuticalsI's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Net Receivables | 4.4 M | 4.2 M |
|
| |||||
| Total Assets | 214.3 M | 285.8 M |
|
| |||||
| Total Current Assets | 175.8 M | 243.4 M |
|
| |||||
| Non Current Assets Total | 38.4 M | 42.4 M |
|
| |||||
| Property Plant Equipment | 5.6 M | 5.3 M |
|
| |||||
| Depreciation And Amortization | 1.5 M | 1.3 M |
|
| |||||
| Selling General Administrative | 19.2 M | 31.2 M |
|
| |||||
| Total Current Liabilities | 11.3 M | 16.2 M |
|
| |||||
| Non Current Liabilities Total | 33 M | 47.1 M |
|
| |||||
| Short Term Debt | 2.5 M | 4.2 M |
|
| |||||
| Long Term Debt | 27.4 M | 34.8 M |
|
| |||||
| Short Term Investments | 159.2 M | 172.2 M |
|
| |||||
| Long Term Investments | 25.3 M | 13.7 M |
|
|
Fusion PharmaceuticalsInc Beneish M-Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Fusion PharmaceuticalsI's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Fusion PharmaceuticalsI in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Fusion PharmaceuticalsI's degree of accounting gimmicks and manipulations.
Click cells to compare fundamentals
About Fusion PharmaceuticalsI Beneish M Score
M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.
Depreciation And Amortization |
|
Fusion PharmaceuticalsI Earnings Manipulation Drivers
Although earnings manipulation is typically not the result of intentional misconduct by the c-level executives, it is still a widespread practice by the senior management of public companies such as Fusion PharmaceuticalsI. It is usually done by a series of misrepresentations of various accounting rules and operating activities across multiple financial cycles. The best way to spot the manipulation is to examine the historical financial statement to find inconsistencies in earning reports to find trends in assets or liabilities that are not sustainable in the future.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Receivables | 428K | 794K | 357K | 1.7M | 4.2M | 4.4M | |
| Total Assets | 69.4M | 310.7M | 252.3M | 219.1M | 285.8M | 214.3M | |
| Total Current Assets | 66.6M | 228.2M | 211.8M | 179.0M | 243.4M | 175.8M | |
| Net Debt | (59.6M) | (90.5M) | (46.2M) | (3.6M) | (11.6M) | (12.2M) | |
| Operating Income | (18.2M) | (37.9M) | (82.0M) | (88.0M) | (99.2M) | (94.3M) | |
| Investments | (456K) | (210.5M) | 39.3M | 25.2M | (80.5M) | (76.4M) |
About Fusion PharmaceuticalsI Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fusion PharmaceuticalsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fusion PharmaceuticalsI using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fusion PharmaceuticalsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Fusion PharmaceuticalsI Piotroski F Score and Fusion PharmaceuticalsI Altman Z Score analysis. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Fusion Stock analysis
When running Fusion PharmaceuticalsI's price analysis, check to measure Fusion PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fusion PharmaceuticalsI is operating at the current time. Most of Fusion PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Fusion PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fusion PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Fusion PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |
Is Fusion PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fusion PharmaceuticalsI. If investors know Fusion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fusion PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.45) | Revenue Per Share 0.032 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (0.49) |
The market value of Fusion PharmaceuticalsInc is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Fusion PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fusion PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Fusion PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fusion PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.